Hayyam Kiratli1, İrem Koç2, Onur Inam2, Ali Varan3, Canan Akyüz3. 1. Ocular Oncology Service, Department of Ophthalmology, Hacettepe University School of Medicine, Sihhiye, 06100, Ankara, Turkey. hkiratli@hacettepe.edu.tr. 2. Ocular Oncology Service, Department of Ophthalmology, Hacettepe University School of Medicine, Sihhiye, 06100, Ankara, Turkey. 3. Department of Pediatric Oncology, Hacettepe University School of Medicine, Ankara, Turkey.
Abstract
PURPOSE: To assess the effectiveness of intra-arterial chemotherapy (IAC), intravenous chemotherapy (IVC), and their combination in the management of group D retinoblastoma. METHODS: This was a retrospective, interventional, comparative, and non-randomized clinical study, including all eyes with primarily treated group D retinoblastoma managed in a single institution from February 2010 to July 2016. Patient demographics, treatment modality (primary enucleation, intravenous chemotherapy, intra-arterial chemotherapy alone or intravenous, and intra-arterial chemotherapy), additional need for consolidation treatments or intravitreal melphalan (IVM) injections, and follow-up time were recorded. The main outcome measure was ocular survival rate after various treatment modalities. RESULTS: Of 87 eyes of 83 consecutive cases, 9 eyes (10.3%) were primarily enucleated, 37 (42.6%) eyes received IVC, 30 (34.5%) eyes had IAC, and 11 (12.6%) eyes were treated with IVC followed by IAC. After a mean 81.1 ± 75.2 weeks of follow-up, enucleation rates were 56.8% in the IVC group, 23.3% in the IAC group, and 36.6% in the IVC + IAC group (p = 0.021). There was no significant difference of ocular survival estimates among these 3 groups at 2 or 5 years (p = 0.998, p = 0.986). With logistic regression analysis, age; gender; disease laterality; administration of IVM, TTT, or cryotherapy; mean dose of IVM; follow-up time; and number of IAC or IVC cycles were not significantly related to the enucleation rate (p > 0.05 for all variables). CONCLUSIONS: Our experience showed that in group D patients, primary IAC achieved ocular survival in 76.7% of eyes, and less need for local consolidation treatments, whereas following primary IVC ocular survival was 43.2%.
PURPOSE: To assess the effectiveness of intra-arterial chemotherapy (IAC), intravenous chemotherapy (IVC), and their combination in the management of group D retinoblastoma. METHODS: This was a retrospective, interventional, comparative, and non-randomized clinical study, including all eyes with primarily treated group D retinoblastoma managed in a single institution from February 2010 to July 2016. Patient demographics, treatment modality (primary enucleation, intravenous chemotherapy, intra-arterial chemotherapy alone or intravenous, and intra-arterial chemotherapy), additional need for consolidation treatments or intravitreal melphalan (IVM) injections, and follow-up time were recorded. The main outcome measure was ocular survival rate after various treatment modalities. RESULTS: Of 87 eyes of 83 consecutive cases, 9 eyes (10.3%) were primarily enucleated, 37 (42.6%) eyes received IVC, 30 (34.5%) eyes had IAC, and 11 (12.6%) eyes were treated with IVC followed by IAC. After a mean 81.1 ± 75.2 weeks of follow-up, enucleation rates were 56.8% in the IVC group, 23.3% in the IAC group, and 36.6% in the IVC + IAC group (p = 0.021). There was no significant difference of ocular survival estimates among these 3 groups at 2 or 5 years (p = 0.998, p = 0.986). With logistic regression analysis, age; gender; disease laterality; administration of IVM, TTT, or cryotherapy; mean dose of IVM; follow-up time; and number of IAC or IVC cycles were not significantly related to the enucleation rate (p > 0.05 for all variables). CONCLUSIONS: Our experience showed that in group D patients, primary IAC achieved ocular survival in 76.7% of eyes, and less need for local consolidation treatments, whereas following primary IVC ocular survival was 43.2%.
Entities:
Keywords:
Group D; Intra-arterial chemotherapy; Intravenous chemotherapy; Intravitreal chemotherapy; Retinoblastoma
Authors: Junyang Zhao; Helen Dimaras; Christine Massey; Xiaolin Xu; Dongsheng Huang; Bin Li; Helen S L Chan; Brenda L Gallie Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: E Bertelli; S Leonini; D Galimberti; S Moretti; R Tinturini; T Hadjistilianou; S De Francesco; D G Romano; I M Vallone; S Cioni; P Gennari; P Galluzzi; I Grazzini; S Rossi; S Bracco Journal: AJNR Am J Neuroradiol Date: 2016-02-25 Impact factor: 3.825
Authors: Christina Scelfo; Jasmine H Francis; Vikas Khetan; Thomas Jenkins; Brian Marr; David H Abramson; Carol L Shields; Jacob Pe'er; Francis Munier; Jesse Berry; J William Harbour; Andrey Yarovoy; Evandro Lucena; Timothy G Murray; Pooja Bhagia; Evelyn Paysse; Samuray Tuncer; Guillermo L Chantada; Annette C Moll; Tatiana Ushakova; David A Plager; Islamov Ziyovuddin; Carlos A Leal; Miguel A Materin; Xun-Da Ji; Jose W Cursino; Rodrigo Polania; Hayyam Kiratli; Charlotta All-Ericsson; Rejin Kebudi; Santosh G Honavar; Vicktoria Vishnevskia-Dai; Sidnel Epelman; Anthony B Daniels; Jeanie D Ling; Fousseyni Traore; Marco A Ramirez-Ortiz Journal: Int J Ophthalmol Date: 2017-06-18 Impact factor: 1.779
Authors: Ido D Fabian; Andrew W Stacey; Tanzina Chowdhury; Catriona Duncan; Esin K Karaa; Irene Scheimberg; M Ashwin Reddy; Mandeep S Sagoo Journal: Ophthalmology Date: 2017-03-13 Impact factor: 12.079
Authors: Swathi Kaliki; Carol L Shields; Duangnate Rojanaporn; Saad Al-Dahmash; John P McLaughlin; Jerry A Shields; Ralph C Eagle Journal: Ophthalmology Date: 2013-02-08 Impact factor: 12.079
Authors: Y Pierre Gobin; Ira J Dunkel; Brian P Marr; Jasmine H Francis; Scott E Brodie; David H Abramson Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240
Authors: David H Abramson; Brian P Marr; Scott E Brodie; Ira Dunkel; Sotiria Palioura; Y Pierre Gobin Journal: PLoS One Date: 2012-04-24 Impact factor: 3.240
Authors: Albert Liao; Terry Hsieh; Jasmine H Francis; Jessica A Lavery; Audrey Mauguen; Scott E Brodie; David H Abramson Journal: Retina Date: 2021-01-01 Impact factor: 3.975